The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor

European Journal of Clinical Pharmacology

Volumn 61, Issue 4, 2005, Pages 247-256

  Sarapa, Nenad ^a   Britto, Margaret R ^b   Mainka, Michelle B ^a   Parivar, Kourosh ^a  

^a PFIZER INC   (United States)

^b IQVIA   (United States)

Author keywords

Hepatic impairment; Pharmacokinetics; Valdecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 3A4; DEETHYLLIDOCAINE; DRUG METABOLITE; LIDOCAINE; LIVER ENZYME; MARKER; SC 66905; UNCLASSIFIED DRUG; VALDECOXIB;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FEMALE; HUMAN; LIVER DYSFUNCTION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX; SMOKING; SOMNOLENCE; STEADY STATE;

ADULT; AGED; AREA UNDER CURVE; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HALF-LIFE; HUMANS; ISOXAZOLES; LIDOCAINE; LIVER DISEASES; MALE; MATCHED-PAIR ANALYSIS; METABOLIC CLEARANCE RATE; MIDDLE AGED; SULFONAMIDES;

EID: 21244469058     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0909-6     Document Type: Article

References (21)

1. Final report for an open label, randomized, single dose crossover study to compare the pharmacokinetics and bioavailability of intravenous and oral tablet valdecoxib formulations in healthy adult subjects. GD Searle & Co, Protocol No. N91-99-02-070; Report No. N91-00-06-070, 12 September 2000 [Pharmacia internal report]
2. Morgan DJ, McLean AJ (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 29:370-391
3. Rodighiero V (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37:399-431
4. Thummel KE, Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE (eds) Goodman and Gilmans' the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 1924-2023
5. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling (May 2003) Guidance for Industry. Center for Drug Evaluation and Research, Food and Drug Administration
6. Validation of a liquid chromatographic/tandem mass spectrometric assay for the quantitation of SC-69124, SC-65872 and SC-66905 in human plasma for Pharmacia by CEDRA Corporation (18 March 2002) Document Number: M2001097 [Pharmacia internal report]
7. The method development and validation of a high performance liquid chromatographic mass spectrometric assay with MS/MS detection for free SC-65872 in human plasma for Searle at Phoenix International Life Sciences Inc (4 August 2000) Document Number: M2099283 [Pharmacia internal report]
8. The method development and validation of a high performance liquid chromatographic mass spectrometric assay with MS/MS detection for SC-65872, SC-66905 and SC-69124 in human whole blood for Searle at Phoenix International Life Sciences Inc (20 March 1998) Document Number: M2097208 [Pharmacia internal report]
9. The method development and validation of a high performance liquid chromatographic mass spectrometric assay with MS/MS detection for SC-65872, SC-66905 and SC-69124 in human urine for Searle at Phoenix International Life Sciences Inc (31 January 2000) Document Number: M2099166 [Pharmacia internal report]
10. George J, Murray M, Byth K, Farrell GC (1995) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21:120-128
11. Blaschke TF (1977) Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 2:32-44
12. Tillement JP, Lhoste F, Giudicelli JF (1978) Diseases and drug protein binding. Clin Pharmacokinet 3:144-154
13. Rowland MF, Blaschke TF, Meffin PJ, Williams RL (1976) Pharmacokinetics in disease states modifying hepatic and metabolic function. In: Benet (ed) The effect of disease states on drug pharmacokinetics. American Pharmaceutical Association, Washington DC, pp 53-75
14. Albengres E, Urien S, Kusmierek J, Tillement JP (1982) Benoxaprofen: plasma binding and binding interactions with some drugs and endogenous compounds. Eur J Rheumatol Inflamm 5:87-92
15. Bergquist C, Lindegard J, Salmonson T (1999) Dosing recommendations in liver disease. Clin Pharmacol Ther 66:201-204
16. Noveck RJ, McMahon FG, Hubbard R., Karim A (2000) Pharmacokinetic effects of celecoxib, a selective cyclooxygenase 2 inhibitor (COX-2), in alcoholic cirrhosis and healthy subjects. Clin Pharmacol Ther 67:164
17. Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38:225-242
18. Schwartz JI, Larson PJ, Gertz BJ, Cote J, Lasseter K, Porras AG (2000) Rofecoxib steady-state pharmacokinetics in moderate hepatic insufficiency patients. Am J Gastroenterol 95:2519
19. Schwartz JI, Larson PJ, Gertz BJ, Cote J, Lasseter K, Porras AG (2001) Steady-state rofecoxib pharmacokinetics in moderate hepatic insufficiency patients. Clin Pharmacol Ther 69:60
20. Agrawal NGB, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC, Lasseter KC, Alam I, Petty KJ, Gottesdiener KM (2003) Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol 43:1136-1148
21. Human pharmacokinetics and bioavailability of valdecoxib: summary report of all data and overall conclusions. GD Searle & Co, Report No. N91-00-07-810, December 2000 [Pharmacia internal report]